Therapeutic use of avidin is not hampered by antiavidin antibodies in humans

Fiorella Petronzelli, Angela Pelliccia, Anna Maria Anastasi, Ragnar Lindstedt, Stefania Manganello, Liliana Elisa Ferrari, Claudio Albertoni, Barbara Leoni, Antonio Rosi, Valeria D'Alessio, Katia Deiana, Giovanni Paganelli, Rita De Santis

Research output: Contribution to journalArticle

Abstract

Hen egg white avidin is increasingly used in the clinic as part of multifactor treatments such as pretargeted radionuclide therapy of cancer or as an antidote of biotinylated drugs. Taking into account that naturally occurring human antiavidin antibodies (HAVA) are common in humans, the present work investigates avidin immunogenicity as part of risk/benefit evaluations. Sera from 139 oncology patients naive to avidin were confirmed to exhibit HAVA with lognormally distributed titers. HAVA were boosted after avidin treatment, with no correlation with the avidin dose or with the basal titer. No antibody-related clinical symptoms were observed in 21 HAVA-positive patients treated with avidin. In mouse models, high mouse antiavidin antibody titers, induced to simulate the worst human condition, neither reduced the biotin uptake of intratissue-injected avidin nor affected the capacity of intravenously injected avidin to clear a biotinylated drug from circulation. In both models the avidin treatment was well tolerated. Results indicate that avidin immunogenicity does not affect its safety and efficacy, thus encouraging its further use in clinical applications.

Original languageEnglish
Pages (from-to)563-570
Number of pages8
JournalCancer Biotherapy and Radiopharmaceuticals
Volume25
Issue number5
DOIs
Publication statusPublished - Oct 1 2010

Keywords

  • antibody
  • avidin
  • HAVA
  • immunogenicity
  • radioimmunotherapy
  • targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology

Fingerprint Dive into the research topics of 'Therapeutic use of avidin is not hampered by antiavidin antibodies in humans'. Together they form a unique fingerprint.

  • Cite this

    Petronzelli, F., Pelliccia, A., Anastasi, A. M., Lindstedt, R., Manganello, S., Ferrari, L. E., Albertoni, C., Leoni, B., Rosi, A., D'Alessio, V., Deiana, K., Paganelli, G., & De Santis, R. (2010). Therapeutic use of avidin is not hampered by antiavidin antibodies in humans. Cancer Biotherapy and Radiopharmaceuticals, 25(5), 563-570. https://doi.org/10.1089/cbr.2010.0797